Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118480 | 0.86 | HCAR3 (0.34) | PI4KBPI4KAHCAR3MAPTTP53 | |
| SCHEMBL1117941 | 0.83 | HCAR3 (0.41) | HCAR3 | |
| SCHEMBL1783498 | 0.83 | HCAR3 (0.43) | HCAR3MAPT | |
| SCHEMBL27857536 | 0.83 | HCAR3 (0.39) | PI4KBPI4KAHCAR3MAPT | |
| SCHEMBL1780133 | 0.83 | HCAR3 (0.39) | PI4KBHCAR3MAPTTP53 | |
| SCHEMBL1117865 | 0.82 | HCAR3 (0.42) | PI4KBHCAR3TP53 | |
| SCHEMBL1117883 | 0.82 | HCAR3 (0.41) | PI4KBPI4KAHCAR3TP53LCK | |
| SCHEMBL692405 | 0.81 | HCAR3 (0.34) | PI4KBPI4KAHCAR3FPR3FPR2 | |
| SCHEMBL1117879 | 0.80 | HCAR3 (0.40) | HCAR3TP53 | |
| SCHEMBL1783367 | 0.80 | HCAR3 (0.37) | PI4KBHCAR3MAPTGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2280982-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | PI4KB 2248/4885PI4KA 2602/4885HCAR3 2774/4885 |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | PI4KB 2248/4885PI4KA 2602/4885HCAR3 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.